AC Immune announces amendment to Eli Lilly license pact, to receive CHF 10M

AC Immune (ACIU) announced an agreement with Eli Lilly (LLY) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer candidates and potential back-up compounds. Under this amendment, AC Immune will receive a CHF 10M upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF1.7B, plus tiered percentage royalty payments in the low double digits, as previously disclosed.